2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
275
Carcinoma, Intraductal, Noninfiltrating
25
Breast Carcinoma In Situ
21
Neoplasm Metastasis
14
Neoplasms
13
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Endometrial Neoplasms
6
Prostatic Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Recurrence
3
Obesity
3
Hot Flashes
3
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sleep Wake Disorders
2
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Interventions
Insulin Glargine
4
Insulin
3
Alpelisib
3
volagidemab
2
Metformin
2
Fulvestrant
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
olaparib
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
Electrocardiography
1
DNA, Ribosomal
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Tamoxifen
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled